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Abstract
Background: Activity of cetuximab, a chimeric monoclonal antibody targeting the epidermal growth factor receptor, 
is largely attributed to its direct antiproliferative and proapoptotic effects. Antibody-dependent cell-mediated 
cytotoxicity (ADCC) could be another possible mechanism of cetuximab antitumor effects and its specific contribution 
on the clinical activity of cetuximab is unknown.
Methods: We assessed immune cells infiltrate (CD56, CD68, CD3, CD4, CD8, Foxp3) in the primary tumor of metastatic 
colorectal cancer (mCRC) patients treated with a first-line cetuximab-based chemotherapy in the framework of 
prospective trials (treatment group) and in a matched group of mCRC patients who received the same chemotherapy 
regimen without cetuximab (control group). The relationship between intra-tumoral immune effector cells, the K-ras 
status and the efficacy of the treatment were investigated. We also evaluated in vitro, the ADCC activity in healthy 
donors and chemonaive mCRC patients and the specific contribution of CD56+ cells.
Results: ADCC activity against DLD1 CRC cell line is maintained in cancer patients and significantly declined after 
CD56+ cells depletion. In multivariate analysis, K-ras wild-type (HR: 4.7 (95% CI 1.8-12.3), p = 0.001) and tumor infiltrating 
CD56+ cells (HR: 2.6, (95%CI:1.14-6.0), p = 0.019) were independent favourable prognostic factors for PFS and response 
only in the cetuximab treatment group. By contrast CD56+ cells failed to predict PFS and response in the control group.
Conclusions: CD56+ cells, mainly NK cells, may be the major effector of ADCC related-cetuximab activity. Assessment 
of CD56+ cells infiltrate in primary colorectal adenocarcinoma may provide additional information to K-ras status in 
predicting response and PFS in mCRC patients treated with first-line cetuximab-based chemotherapy.
Background
Cetuximab is a chimeric immunoglobulin G 1 (IgG1)
monoclonal antibody (mAb) which binds the epidermal
growth factor receptor (EGFR) with high affinity and
inhibits ligand binding [1]. Cetuximab is active in chemo-
therapy resistant metastatic colorectal cancer (mCRC)
[2,3] and enhances response rate and progression-free
survival (PFS) in first-line therapy in combination with
Folfiri and Folfox [4,5]. Clinical studies of cetuximab ther-
apy in mCRC have failed to show a significant correlation
between EGFR-staining intensity and patients' response
to cetuximab treatment [2,3]. Therefore, identifying
molecular markers that can select patients who are likely
to benefit from cetuximab is crucial to avoid chemother-
apy toxicity and reduce treatment cost. Recently the
absence of K-ras mutation appears to be a reliable marker
in predicting cetuximab efficacy, both in first-line and in
third-line of the anti-EGFR therapies [4-8]. Other factors
such as, EGFR amplification [9-11], epiregulin and
amphiregulin expression [12], nuclear factor-kB tumor
expression [13], PTEN [14], BRAF [15] or PIK3CA [16]
were also suggested to predict response to cetuximab but
these additional biomarkers require further validation
before incorporation into clinical practice.
The activity of cetuximab has largely been attributed to
the direct antiproliferative and proapoptotic effects of the
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antibody. However, another possible mechanism of its
antitumor effects is mediated through antibody-depen-
dent cell-mediated cytotoxicity (ADCC). The ADCC
mediated through Fc receptors (FcγR) carried by NK
cells, macrophages and polymorphonuclear leukocytes, is
a well-recognized immune effector mechanism in the
antitumor effect of IgG1 [17]. Of these cells, NK cells rep-
resent the principal ADCC effector cells [18,19]. Recently,
some polymorphisms on genes encoding for activating
receptors FcγRIIa and FcγRIIIa were found to affect the
clinical efficacy of cetuximab [20,21]. The recruitment of
Foxp3-positive regulatory T cells (Treg) into tumor likely
represents one of the mechanisms by which malignant
cells evade host immune response. The intratumoral den-
sity of foxp3 as been reported to be associated with over-
all survival [22]. Once activated, Tregs can inhibit the
function of dendritic cells, NK cells, B cells and other
immune cells [23-25] and consequently alter ADCC
activity.
Based on the potential value of ADCC in cetuximab
activity, we assessed in mCRC patients, the role of
peripheral blood mononuclear cells (PBMC) and their
CD56+ subpopulation in ADCC activity and we evalu-
ated the relationship between the intratumoral immune
cells and the efficacy of first-line cetuximab-based che-
motherapy.
Methods
Patients and tissue samples
a retrospective study review was conducted from data in
our institution's prospectively collected gastrointestinal
cancer database. Chemonaive patients with mCRC who
underwent surgical resection of their primary tumor and
diagnosed with synchronous metastases were included in
the analysis. We analyzed the primary tumor of 33
chemonaïve mCRC patients treated with first-line cetux-
imab (Erbitux®, Merck, Darmstadt, Germany) containing
chemotherapy regimen in the framework of phase II and
I I I  s t u d i e s.  P a t i e n t s  r e c e i v e d  m o s t l y  s t a n d a r d  F O L F I R I
regimen or FOLFOX accordingly to study recommenda-
tions [4,26,27]. Thirty-five chemonaïve mCRC patients
with synchronous metastasis, who underwent resection of
the primary tumor before starting a similar chemother-
apy regimen that did not contain cetuximab were used as
control group. The treatment and the control group were
case-matched for the following parameters: sex, age, pri-
mary tumor location, tumor stage, performance status,
metastatic sites, type of chemotherapy administered and
treatment duration.
Formalin-fixed and paraffin-embedded (FFPE) samples
of the primary tumor were obtained for immunohis-
tochemical and PCR analysis.
The study was approved by the ethic committee of the
Erasme University Hospital and all patients provided
written informed consent.
Clinical evaluation and tumor response criteria
We considered PFS to assess the cetuximab-based che-
motherapy efficacy in first line and not OS which is influ-
enced by second and third-lines chemotherapy and liver
mets surgery. Tumor response was evaluated by comput-
erized tomodensitometry according to the Response
Evaluation Criteria in Solid Tumors (RECIST) [28] and
classified in complete response (CR), partial response
(PR), stable disease (SD) and progressive disease (PD).
The overall best response (OR) was defined as the best
response recorded from the start of the treatment until
disease progression, recurrence or start of the new ther-
apy. Response was centrally confirmed in the setting of
the referenced trials. For the analysis, CR and PR patients
were grouped in responders; patients with SD and PD
were grouped in non-responder patients.
Immunohistochemical assessment
Hematoxylin & eosine sections of the tumors were exam-
ined by a pathologist for confirmation of the histologic
diagnosis and the optimal block donors selected. The
FFPE tissues were deparaffinized in xylene, and rehy-
drated in graded alcohols and water. Colorectal tumor
sections were incubated with monoclonal antibodies
against CD3, CD4, CD8, CD56, CD68, Foxp3 and EGFR
and DAB-chromogen were applied (Dako, Copenhagen,
Denmark) (Additional file 1: supplemental Table S1).
Appropriate negative and positive controls were used.
Evaluation of Immunohistochemical variables
The slides were examined independently by two observ-
ers (RM, NN) blinded to both clinical and pathologic
data. Twenty representative fields of the tumour invasive
margin (IM) were chosen from each slide, and the stained
cells were counted by means of a 10×10 ocular grid at ×
200 magnification (observed area 0.25 mm2) using confo-
cal microscopy. For each case, the total number of CD3,
CD8, CD4, FOXP3, CD56, CD68 positive cells (repre-
senting lymphocytes T (LT), LTCD8, LTCD4, Treg, natu-
ral killers (NK) and macrophages, respectively) per
square millimeter was calculated. Variations in the enu-
meration within a range of 5% were re-evaluated and a
consensus decision was made.
Expression of EGFR was quantified using a visual grad-
ing system based on the extent of staining ( percentage of
positive tumor cells graded on scale of 0 to 3: 0, none; 1,
1-30%, 2, 31-60%, 3, > 60% ) and the intensity of staining
(graded on a scale of 0 to 3: 0, none; 1, weak staining; 2,
moderate staining; 3, strong staining ). Membranous and
cytoplasmic staining were evaluated.Maréchal et al. BMC Cancer 2010, 10:340
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DNA extraction and mutation analysis
Presence of tumor cells (> 75%) in each tumor block was
firstly histologically controlled by H & E coloration.
Thereafter, DNA was extracted from FFPE samples after
macrodissection. The presence of K-ras was determined
by allelic discrimination assay on a 7500HT Real Time
PCR System. K-ras mutations located within the codon
12 (n = 6) and 13 (n = 1) were screened for. All mutations
were confirmed by direct sequencing (8).
Cell Lines and cell culture
The EGFR overexpressing DLD1 colorectal glandular car-
cinoma cell line was obtained from the American T ype
Culture Collection (Manassas, VA, USA). DLD1 has been
previously found to carry mutated K-ras. To confirm that
DLD1 indeed harbour mutated K-ras alleles, we extracted
the corresponding genomic DNA and sequence the K-ras
locus. We confirmed that DLD1 display Gly13Asp K-ras
mutation (data not shown).The DLD1 cells were main-
tained in RPMI 1640 (Sigma, St Louis, MO, USA) supple-
mented with 10% heat-inactivated foetal bovine serum
(FBS, Gibico BRL, Grant Island, NY, USA), sodium pyru-
vate 1%, 100 units/ml penicillin and 100 μ g/ml strepto-
mycin. The expression of EGFR by the DLD1 cell line was
confirmed by immunocytochemistry (data not shown)).
Preparation of human peripheral blood mononuclear cells 
(PBMC)
PBMC from 5 healthy medication-free donors (3 male, 2
female; mean age: 33.8 years, range:27-48 years) and 5
chemonaïve mCRC patients (2 female, 3 male, mean age
55.4 years, range 49-61 years) were isolated from hepa-
rinised peripheral blood on a Ficoll gradient.
Flow cytometry analysis
Immunophenotyping of PBMCs before and after deple-
tion of CD56+ cells was performed by incubation with
appropriate combination of fluorochrome-labeled mono-
clonal antobodies. Major lymphocyte populations CD3+ ,
CD3+ CD4+ , CD3+ CD8+ , CD3 - CD16+ 56+ (NK),
CD3+ CD16+ 56+ (NKT), CD19+ (B) were determined
by two cocktails MoAb: anti-CD45 PerCP, anti-CD3
FITC, anti-CD8 PE, anti-CD4 APC and anti-CD45 PerCP,
anti-CD3 FITC, anti-CD16+ 56 PE and CD19 APC. Data
acquisition was performed with a FacsCanto flow cytom-
eter and data analysed using BD FacsDiva software (BD
Biosciences, Mountain View, CA).
Purification of effector cells and interleukine-2(IL-2) 
treatment
Highly depleted PBMC from CD56+ cells (CD56 depleted
PBMC), were obtained by magnetic activated cells sort-
ing (MACS) using the system from Miltenyi Biotec
according to the manufacturer's instructions. The CD56
depleted PBMC and non depleted PBMC were used sepa-
rately in ADCC assays. Between 92% to 94% of the CD56+
cells were sorted after MACS depletion. As IL-2 is known
to activate PBMC, we tested the effect of human recom-
binant IL-2 (R & D Systems) on cetuximab-mediated
ADCC in CD56 depleted and non depleted PBMC. The
two populations were cultured in medium alone or
enriched with rhuIL-2 (10 ng/ml) for 18 h prior to use in
ADCC assays.
ADCC assay
5 × 104target cells/well were plated in a 96 flat bottom
wells plate in 200 μ l of medium, 24 hours before adding
effectors cells. Human PBMC (effector) or IL-2 activated
PBMC, were added at different E:T ratios ranging from
20:1 to 2:1 and incubated for 24 h. Cetuximab or poly-
clonal human IgG (Sigma, St Louis, MO, USA) were
added to the individual wells at different concentrations
ranging from 0 to100 μ g/ml.
Accordingly to Heo et al., cytotoxicity was evaluated
using a 3-(4,5 dimethyltiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) colorimetric assay [29,30] (addi-
tional file 2). Experiments conducted in a preliminary
phase to select optimal conditions for the ADCC effect
showed that (a) target cells were not killed after exposure
to cetuximab in the absence of PBMC (b) 10 μ g/ml was
the optimal cetuximab concentration for saturating
ADCC assay by PBMC.
Statistical Analysis
The PFS was estimated by the Kaplan-Meier method and
the two groups were compared with by the log-rank test.
For all immunohistochemical markers, the cut off for def-
inition of subgroups was the median value. The non-
parametric χ2 test and the Fisher's exact tests were carried
out as appropriate to compare categorical variables. The
Mann-Witney U test was used for the comparison of the
treatment and the control groups regarding the tumor
infiltrating immune cells and ADCC activity. Correlations
were analyzed by Spearman's correlation coefficient test.
Multivariate analyses used a step-down procedure based
on the likelihood ratio test. A p-value ≤ 0.1 in univariate
analysis was required to consider the variable for multi-
variate analysis. The Two-tailed p < 0.05 was judged to be
significant. All analysis were performed with SPSS 10.0
software (SPSS, Chicago, Il).
Results
Patients characteristics
The baseline and treatment characteristics of patients
from treatment and control group are summarized in
table 1. The two groups were similar regarding all vari-
ables matched including the proportion of patients
treated with the FOLFIRIMaréchal et al. BMC Cancer 2010, 10:340
http://www.biomedcentral.com/1471-2407/10/340
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Immune cells infiltrate in primary CRC and treatment 
efficacy
Positive CD4, CD3, CD8, CD68 and Foxp3 cells were
detected in 33/33 (100%) tumor samples (figure 1) and
their mean number were similar between the two patient
groups (table 2). The number of intratumoral mac-
rophages (CD68+ cells) and Lymphocytes (CD3+ ,CD4+
,CD8+ , Foxp3+ cells) were similar between responders
and non responders and we found no association with the
PFS both in the treatment and the control group (table 3).
For CD56+ cells, two distinct immunologic pattern
were clearly observed consisting in, either tumors with
strongly positive CD56 staining (CD56 positive tumors)
or tumors with undetectable CD56 staining (CD56 nega-
Table 1: Patients characteristics
Variables Treatment group (n = 33) Control group (n = 35) p-value
Age, median (range) 59 (43-75) 62 (41-78) 0.74
Sex, n
Male 19 20
Female 14 15 0.97
ECOG PS, median (range) 0 (0-1) 0 (0-2) 0.37
Primary tumour location
Right 11 11
Transverse 1 2
Left 18 19
rectum 3 3 0.91
Metastatic sites
Liver 24 26
Lymph nodes 7 8
Lung 2 1 0.98
Chemotherapy regimen
Folfiri + cetuximab 32 0
Folfiri 0 33
Folfox + cetuximab 1 0 0.94
Folfox 0 2
Overall Best Response
CR 2 1
PR 14 15
SD 6 9
PD 11 10 0.36
Treatment duration
months, median 4.9 5.3 0.51
PFS
Months, median 5.7 5.4 0.52
Abbreviations: NS: non significant, ECOG PS: Eastern Cooperative Oncology Group Performance Status.Maréchal et al. BMC Cancer 2010, 10:340
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tive tumors) (figure 1).These two pattern were found both
in the treatment and the control groups (table 2) and
were compared for OR and PFS and correlated with the
K-ras status. In the control group, no difference has been
d e t e c t e d  i n  O R  a n d  P F S  b e t w e e n  p a t i e n t s  w i t h  C D 5 6
negative tumor cells and those with CD56 positive tumor
(table 3, figure 1). By contrast, in the treatment group,
CD56 positive tumors were more frequent in responder
than in non-responder patients (10/16 (63%) versus 3/19
(18%), p = 0.011) and patients with CD56 positive tumor
had a longer PFS than those with CD56 negative one (8.8
months (95% CI: 3.3-13.5) versus 3.9 months (95% CI:
3.1-4.7)) (p = 0.005) (table 3). Neither the CD56 tumor
status (r = -0.267, p = 0.134) and the number of CD56+
cells (r = -0.295, p= 0.101) were correlated with the K-ras
status of the tumor.
EGFR expression
as previously observed, no significant correlation was
found between EGFR expression, OR rate and PFS.
Figure 1 Sections of colorectal adenocarcinoma with results of the immunostaining: CD3, CD4, CD8, CD56, Foxp3 (magnification × 100). 
The CD56- section (magnification X40) reveals no CD56 positive immune cells (considered as NK negative tumor) but staining of Meisner plexus used 
as interne positive control.
       
CD4
+
CD56
+
CD3
+
Foxp3
+
CD8
+
CD56
-
Table 2: Mean numbers of tumor-infiltrating immune cells in treatment and control groups
Variables Treatment Group Control Group Treatment vs Control 
group
Mean Median Mean Median p-value
cells/mm2 cells/mm2 cells/mm2 cells/mm2
(SD) (range) (SD) (range)
CD3+ 139 (108) 99 (0-340) 106 (89) 144 (0-410) 0.82
CD4+ 33 (27) 42 (0-114) 24 (19) 28 (0-82) 0.21
CD8+ 111 (106) 65 (29-331) 126 (101) 68 (28-361) 0.71
CD68+ 171 (80) 88 (31-465) 139 (127) 151 (22-385) 0.27
Foxp3+ 43 (36) 40 (14-150) 114 (101) 76 (12-228) 0.54
CD56+ 6.4 0 (0-18) 5.6 0 (0-15) 0.32
Abbreviations: SD: Standard DeviationMaréchal et al. BMC Cancer 2010, 10:340
http://www.biomedcentral.com/1471-2407/10/340
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K-ras mutation Status and treatment efficacy
K-ras mutations were detected in the tumor of 13/33
(39%) patients from the cetuximab treatment group. Wild
type (WT) status was found in 13/16 (81%) responders
and in 7/17 (41%) non responders (p = 0.008). WT group
had a prolonged PFS (9.2 months (95% CI: 4.9 to 16.4)) as
compared to the mutated group (4.5 months (95% CI: 2.6-
6.2; p = 0.0007) (table 3).
Multivariate analysis
CD56+ cells infiltrate and WT K-ras status were indepen-
dent predictors of OR. Both CD56 negative tumors (Haz-
Table 3: Univariate and multivariate analysis of factors associated with OR and PFS
UNIVARIATE ANALYSIS
Variables OR PFS
HR (95% CI) p-value HR (95%CI) p-value
Treatment Group
CD3+ 0.80 (0.20-3.25) 0.70 0.94 (0.45-1.94) 0.91
CD4+ 1.31 (0.32-1.49) 0.36 0.74 (0.35-1.58) 0.41
CD8+ 0.86 (0.22-3.58) 0.74 0.84 (0.45-1.72) 0.62
CD56+ 7.75 (1.13-42.6) 0.012 2.70 (1.25-5.88) 0.005
CD68+ 1.25 (0.79-7.72) 0.55 1.16 (0.55-2.46) 0.69
Foxp3+ 0.54 (0.20-3.50) 0.98 0.89 (0.43-1.83) 0.81
K-ras status
WT vs MT 12.81 (2.15-7.7) 0.008 4.36 (1.77-10.7) 0.0007
Control Group
CD3+ 0.91 (0.41-4.11) 0.63 0.84 (0.38-3.98) 0.74
CD4+ 1.51 (0.61-2.74) 0.54 0.94 (0.52-2.98) 0.52
CD8+ 1.32 (0.59-2.42) 0.31 1.20 (0.59-2.31) 0.76
CD56+ 1.21 (0.74-2.07) 0.29 1.11 (0.81-1.56) 0.14
CD68+ 0.84 (0.58-2.11) 0.36 0.87 (0.44-3.52) 0.27
Foxp3+ 0.66 (0.34-1.92) 0.68 0.71 (0.88-1.56) 0.13
MULTIVARIATE ANALYSIS
Variables OR PFS
HR (95% CI) p-value HR (95%CI) p-value
CD56
Negative 1 1
Positive 7.05 0.04 2.62 0.0019
(1.49-45.76) (1.14-6.00)
K-ras
Mutated 1 1
Wild Type 11.7 0.013 4.74 0.001
(1.77-8.33) (1.8-12.3)
Abbreviations: CI: Confident interval, MT: mutated, WT: wild type, OR: overall response rate, PFS: Progression-free survivalMaréchal et al. BMC Cancer 2010, 10:340
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ard ratio: 2.6 (95% CI: 1.14-6.00); p = 0.019) and K-ras
mutations (Hazard ratio: 4.74 (95% CI: 1.8-12.3); p =
0.001) contribute as significant independent negative
prognostic factors for the PFS (table 3). Interestingly, in
the group of WT K-ras tumors (n = 20), there is a trend
for a higher OR and a prolonged PFS in patients with
CD56 positive tumor as compared with CD56 negative
tumor patients and the whole group (CD56+ and CD56- )
(additional file 3, Supplemental Table S2).
Cetuximab-mediated ADCC in vitro activity is maintained 
in mCRC patients
CD56+ cells represented a minor fraction (range between
5 and 14%) of the whole PBMC population.
Adjunction of cetuximab enhanced the cytotoxicity of
P B M C  ( A D C C )  a s  c o m p a r e d  t o  t h e  P B M C  a c t i v i t y
(PBMC alone). At the higher E:T ratios of 10:1 and 20:1,
cetuximab enhanced tumoral cell lysis, as compared to
the baseline activity of PBMC; both in healthy volunteers
(p = 0.008 at an E:T ratio of 10:1,from 26% to 60%; and p =
0.009 at an E:T ratio of 20:1, from 30% to 74%) and in
mCRC patients (p = 0.001 at an E:T ratio of 10:1,from
19% to 56%; and p = 0.002 at an E:T ratio of 20:1 from
25% to 71%) (figure 2 and 3B). PBMC activity was not
increased by the control antibody. Interestingly, PBMC
and ADCC activity was similar between mCRC patients
and healthy volunteers.
CD56+ cells are responsible for cetuximab-mediated ADCC 
in vitro activity and its majoration by IL-2
While CD56+  cells represent a minor fraction of the
PBMC, depletion of CD56+ cells significantly reduced the
ADCC activity at the different E:T ratio (p < 0.05 at all
E:T ratios) even after IL-2 stimulation (figure 3C, 3D)
underlying the major role of this immune cells in ADCC
activity.
Discussion
One of the most important mechanisms of cetuximab
and panitumumab, the monoclonal antibodies that target
the EGFR, is through the inhibition of the EGF receptor/
ligand interaction. The other pathway through which
cetuximab only, as an IgG1, may exert its antitumor effect
is ADCC [12,14]. Several in vitro and in vivo studies have
shown that this chimeric IgG1 mAb binds to the antigen,
the EGFR, on the surface of tumor cells while its Fc por-
tion binds to the immune effector cells through FCγ R.
Consequently, this binding activates the immune cells
leading to tumor cells killing. ADCC activity of mAbs has
been well described for trastuzumab, a human IgG1 anti
human EGFR 2 (Her-2) antibody and for rituximab, a chi-
meric IgG1 mAb for B-cell differentiation antigen CD20
[31-33].
The array of cellular effectors potentially exerting
ADCC includes the CD3- CD56+ NK lymphocytes [34]
but also CD3+ CD16+ T-cell subset [35], CD16+ CD33+
macrophages [36] and CD16+ granulocytes [37]. Among
the mononuclear cells (MNC), the NK cells (CD3- CD56 +
) play a predominant role in the ADCC through low affin-
ity type II (Fcγ RIIc) and type IIIA (Fcγ RIIIa) Fc receptors
present on their surface [38,39]. The polymorphonuclear
cells are also able to induce ADCC by the engagement of
their CD32 receptor but needs higher concentration lev-
els of antibody compare with the MNC.
Since only less than 50% of WT-Kras mCRC patients
seem to benefit from cetuximab-based treatment, it may
be highly relevant to identify other biomarkers than K-ras
status to predict cetuximab efficacy. To this end, the eval-
Figure 2 PFS according to tumor CD56 status in the treatment group (A) and the control group (B).
A.                                                                                                               B. 
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uation of the ADCC actors as putative surrogate markers
of cetuximab-based therapy seems to be attractive. As
there is still debate whether ADCC plays a role in meta-
static cancer patients who mostly have suppressed
i m m u n e  f u n c t i o n ,  w e  c h o o s e  t o  e v a l u a t e  c e t u x i m a b -
mediated ADCC activity in front-line chemonaïve mCRC
patients. We only used an EGFR+ cell line and no control
EGFR-  cell since the activation of ADCC activity by
cetuximab requires the expression of its target, the EGFR
[40]. Our functional assay provided evidences that CD56+
cells are the main effectors of cetuximab-mediated
Figure 3 Cytotoxicity against colorectal cancer cell line mediated by cetuximab. A-B: PBMCs from healthy volunteers (n = 5, mean age 31 years) 
and from 5 mCRC patients (n = 5) mean age 52 years) were tested for cytotoxicity against DLD1, using four E:T ratio in the absence (PBMCs activity) or 
presence of cetuximab (10 μ g/ml). Points mean of a triplicate experiment; bars: SD. C-D: PBMCs from 5 healthy donors and 5 mCRC were tested for 
the cytotoxicity in the presence or the absence of cetuximab, for the effect of IL-2 stimulation and CD56+ cells depletion. Columns, mean; bars, SD
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ADCC in mCRC patients. Furthermore, the PBMC of
mCRC were capable to initiate ADCC comparable to
healthy donors suggesting that their function is main-
tained. Furthermore, we observed a significant in vitro
ADCC activity despite the mutated K-ras status of the
DLD1 cell line. Our results are thus in accordance with a
recent report showing that cetuximab-related ADCC is
irrespective of the K-ras status [40]. This property could
be exploited particularly in patients with K-ras-mutated
tumors, who otherwise have a low probability of respond-
ing to cetuximab [4,6,7]. In this way, approaches to
enhance ADCC activity, such as immunostimulation and
new generation of EGFR-directed mAbs, may be promis-
ing in the management of this subset of patients.
Whether ADCC contributes to the clinical efficacy of
cetuximab, remains to be determined. Indeed, cetuximab
and panitumumab displayed similar clinical activity
despite the fact that panitumumab is a fully human IgG2
monoclonal antibody with low ability to recruit immune
cells compared to IgG1. The adding value of cetuximab-
mediated ADCC might deserve direct comparison
between cetuximab and panitumumab. On the other
hand, two studies have demonstrated that FCγ R gene
polymorphisms (Fc R3A-V158F and Fc R2a-H131R) are
associated with clinical outcome (response rate and PFS)
in mCRC patients treated with cetuximab administered
in combination with irinotecan or as a single-agent
[20,21]. These findings may support the contribution of
ADCC in cetuximab efficacy. In this line, it would be
helpful to identify which surrogate markers may help us
to predict this contribution to efficacy.
Complementary to our in vitro assay, we observed that
the OR and PFS were significantly higher in patients with
CD56 positive tumors as compared with CD56 negative
tumors. This was not observed in a matched control
group. Nevertheless, only evaluation in prospective ran-
domized trials may confirm that CD56 tumor status is
specifically predictive for ADCC contribution and not
only prognostic.
When adjusted for K-ras status in multivariate model,
the CD56 tumor status remains an independent marker
of response to treatment (OR) and of better PFS and
could be therefore of additional interest in predicting
enhanced cetuximab activity in the WT population.
Our data raise additional questions regarding the role
of NK cells. The phenotype and properties of tumor-infil-
trating NK cells seems to be different from that of periph-
eral NK cells. Peripheral NK cells are CD3-  CD56low
CD16+  while intratumoral NK cells are usually CD3-
CD56bright CD16 - and unable to do ADCC [41,42]. The
number of intratumoral CD56+ cells was found to be low
(mean number: 6.4/mm2 and 5.6/mm2 in the treatment
and the control group respectively) and it may be thus
questionable how this small number can truly impact on
CTX efficacy. However, while the circulating CD56+ cells
represent a minor fraction of PBMC, we observed in vitro
that their low number does not preclude for ADCC
intensity. Additionally, some studies have evidenced sig-
nificant immune cells recruitment into the tumors after
trastuzumab or rituximab based therapy [38,43,44] even
when trastuzumab was associated with immunosuppres-
sive chemotherapy [38]. This recruitment was more sig-
nificant in tumors exhibiting higher in situ infiltration
lymphocytes infiltrate at the baseline [44]. All together,
these data suggest that intratumoral CD56+ cells might be
a surrogate marker of subsequent recruitment.
Conclusions
In summary, the presence of tumor-infiltrating CD56+
cells is an independent predictor for PFS and OR in
mCRC patients treated with first line cetuximab based-
chemotherapy. This suggests that ADCC, mainly through
its central effector, the NK cells, could influence response
to cetuximab-based chemotherapy. The exact relation-
ship between TIL of the primary cancer and peripheral
NK cells activity should be further explored, notably in
assessing the role of ADCC in the adjuvant setting in
patients treated with cetuximab.
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